MRNA Maintained at Neutral by UBS, Price Target Raised to $45

Analysts at UBS maintained their Neutral rating on Moderna (MRNA) on May 4, 2026, but raised their price target significantly. The new target of $45 per share represents a 25% increase from the previous $36 target. This MRNA analyst rating adjustment reflects UBS’s cautious stance on the biotech giant despite recognizing upside potential. Moderna trades at $47.30 with a market cap of $18.8 billion. The stock has climbed 4.25% today and 69.9% over the past year, though it remains below its 52-week high of $59.55.

UBS Maintains Neutral Stance on MRNA

Rating Action and Price Target Boost

UBS kept its Neutral rating intact while raising the price target from $36 to $45. This mixed signal suggests the analyst sees value but remains cautious about near-term catalysts. The $45 target implies modest upside from current levels. UBS raised its price target to $45 from $36, signaling confidence in Moderna’s longer-term prospects. The MRNA analyst rating reflects balanced risk-reward dynamics in the biotech sector.

Market Context for the Rating

Moderna’s stock has performed strongly year-to-date, gaining 60.4% and 69.9% over one year. However, the company faces profitability challenges with negative earnings per share of -$7.26. UBS’s Neutral stance acknowledges both the company’s vaccine pipeline strength and its current financial headwinds. The rating maintains consistency with broader analyst consensus, where 18 analysts rate MRNA as Hold versus only 3 Buy ratings.

Financial Performance and Meyka Grade

Profitability Challenges Persist

Moderna reported negative net income and operating cash flow, reflecting heavy R&D spending on pipeline development. The company’s net profit margin stands at -1.44%, while operating margin is -1.53%. Despite these losses, Moderna maintains a strong balance sheet with $13.18 in cash per share. The company’s debt-to-equity ratio of 0.18 provides financial flexibility for continued investment in vaccine and therapeutic development.

Meyka AI Stock Assessment

Meyka AI rates MRNA with a grade of B, suggesting a Hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 64.7 out of 100 reflects Moderna’s mixed fundamentals. These grades are not guaranteed and we are not financial advisors. The rating acknowledges Moderna’s innovation pipeline while recognizing current profitability concerns.

Analyst Consensus and Technical Signals

Broader Analyst Coverage

Moderna’s analyst consensus leans cautious, with 18 Hold ratings, 3 Buy ratings, and 3 Sell ratings among tracked analysts. The consensus score of 3.0 reflects this mixed outlook. UBS’s Neutral rating aligns with the majority view. The MRNA analyst rating landscape shows investors remain divided on the company’s near-term prospects despite long-term vaccine potential.

Technical and Valuation Metrics

Moderna trades at a price-to-sales ratio of 8.49 and price-to-book of 2.54, both elevated for a company with negative earnings. The RSI of 41.4 suggests the stock is neither overbought nor oversold. Bollinger Bands show the stock trading near the middle band at $50.94, indicating neutral momentum. Forecasts suggest potential movement toward $54.96 yearly and $102.63 in three years, though these projections carry uncertainty.

Pipeline and Strategic Positioning

Vaccine and Therapeutic Portfolio

Moderna’s strength lies in its diversified pipeline spanning respiratory vaccines, latent vaccines, and cancer therapeutics. The company has partnerships with AstraZeneca, Merck, and Vertex Pharmaceuticals. Revenue per share of $5.63 reflects ongoing commercial activity despite profitability challenges. The company’s R&D spending at 131% of revenue shows aggressive investment in future growth drivers.

Path to Profitability

UBS’s price target increase suggests confidence in Moderna’s ability to achieve profitability as pipeline programs mature. The company’s free cash flow remains negative at -$4.01 per share, but improving cash generation could support the analyst’s optimism. Moderna’s 5,800 employees and Cambridge headquarters position it as a leading mRNA technology platform for the biotech industry.

Final Thoughts

UBS raised Moderna’s price target to $45 with a Neutral rating, balancing pipeline strength against profitability challenges. Trading at $47.30, the stock shows mixed analyst sentiment with 18 Hold ratings dominating. While UBS sees upside potential, investors should wait for clearer profitability signals and monitor upcoming earnings before increasing exposure to this innovative biotech company.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.